Evaluation of seventeen patients with COVID-19 pneumonia treated with anakinra according to HScore, SOFA, MuLBSTA and Brescia-COVID respiratory severity scale (BCRSS) scoring systems.

BACKGROUND: Covid-19 pandemic has been affecting whole world by increasing morbidity and mortality rate day by day. Treatment algorithms have been attempted as parallel to the increasing experience with Covid-19. In the pathogenesis of this virus proinflammatory cytokine storm has been called to have the main role. The right timing should be made for treatments. We proposed IL- 1 blocking by anakinra in seventeen Covid-19 patients at high risk of worsening. METHODS: Patients were assessed according to HScore, SOFA [Sequential Organ Failure Assessment Score= SOFA], MuLBSTA Score (Multilobular infiltration, Hypo-Lymphocytosis, Bacterial coinfection, Smoking history, hyper-Tension, and Age), Brescia-COVID respiratory severity scale (BCRSS). RESULTS: In our study, mortality rate was 17.6%. Consequently, 1 (5.9%) patient was receiving low-flow oxygen supply, 3 (17.6%) patients needed no longer oxygen supply and 10 (58.8%) patients were discharged from hospital. CONCLUSION: According to results of our study in the manner of general evaluation; we found that SOFA, MuLBSTA and BCRSS scores were one step ahead according to HScore being insufficient to determine early phases of the disease. In our opinion, the prominent factors those emphasize the use of Anakinra could be listed as comorbidity, risk or presence of secondary infection, ongoing malignant disease. However, the other factors those enhance the use of Anakinra in the situation of viremia also could be sorted as no response to full dose antivirals, antiviral side effects or no success to antiviral treatment. This article is protected by copyright. All rights reserved.